Results 11 to 20 of about 6,882 (175)

Efektivitas Eltrombopag dalam Penanganan Anemia Aplastik Berat pada Anak [PDF]

Sari Pediatri
Latar belakang. Efektivitas pemberian eltrombopag pada kasus anemia aplastik berat pada anak masih kontroversial. Tujuan. Melakukan telaah kritis untuk melihat efektivitas pemberian eltrombopag dalam penanganan anemia aplastik berat pada anak.
Mega Septiana, Teny Tjitra Sari
doaj   +2 more sources

Prediction of Clinical Transporter‐Mediated Drug–Drug Interactions via Comeasurement of Pitavastatin and Eltrombopag in Human Hepatocyte Models [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2020
A structurally identifiable micro‐rate constant mechanistic model was used to describe the interaction between pitavastatin and eltrombopag, with improved goodness‐of‐fit values through comeasurement of pitavastatin and eltrombopag.
Simon J. Carter, Bhavik Chouhan, Pradeep Sharma, Michael J. Chappell   +3 more
doaj   +3 more sources

Recurrent Coronary Thrombus in a Patient with Chronic Immune Thrombocytopenia with Treatment Using Eltrombopag

Case Reports in Cardiology, 2019
Background. Eltrombopag, a nonpeptide thrombopoietin receptor agonist (TPO-RA), has been reported to be an effective therapy for chronic immune thrombocytopenia (ITP).
Terumori Satoh, Masao Saotome, Kenichiro Suwa, Hayato Ohtani, Yasuyuki Nagata, Takaaki Ono, Yuichiro Maekawa   +6 more
doaj   +2 more sources

Refractoriness to eltrombopag in adult primary immune thrombocytopenia: utility of next-generation sequencing techniques [PDF]

Blood Vessels, Thrombosis & Hemostasis
: Thrombopoietin receptor agonists, for example eltrombopag, are standard second-line treatment for immune thrombocytopenia (ITP). Eltrombopag has demonstrated high response rates, both in clinical trials and in routine practice studies.
Tomás José González-López, Ricardo Sanchez, Carmen Pastoriza, Pavel Olivera, Silvia Bernat, Fernando Fernandez-Fuertes, Isabel Socorro Caparrós-Miranda, Gloria Pérez-Rus, Isidro Jarque, Maria Esperanza Moreno-Beltrán, Emma López-Abadía, Erik De Cabo, Shally Marcellini, Gloria Pérez-Segura, Carmen Fernández-Miñano, María Jesús Peñarrubia, Sergio Matarraz, María Pérez-Caro, Alberto Orfao, Drew Provan, Joaquín Martínez-López   +20 more
doaj   +3 more sources

Evaluation of Eltrombopag in Thrombocytopenia Post Hematopoietic Cell Transplantation: Rertrospective Observational Trial

Hematology/Oncology and Stem Cell Therapy, 2022
Background: Thrombocytopenia remains a life-threatening late complication of HCT with an incidence of 5—20%. Currently, there is no approved drug for the treatment of persistent thrombocytopenia post HCT and platelet transfusion is the maintain stay of ...
H. Samarkandi, M. Al Nahedh, A. Alfattani, F. Alsharif, N. Bakshi, W. Rasheed, F. Alfraih, M. Alhumaid, Nora Alkhudair, S. Alhayli, H. Alsaedi, M. Shaheen, A. Hanbali, S.K. Hashmi, E. Devol, A. Alseraihy, H. Alzahrani, M. Aljurf   +17 more
doaj   +2 more sources

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome

Platelets, 2021
Thrombocytopenia is a severe complication for patients with myelodysplastic syndrome (MDS). Eltrombopag increases platelet count in MDS patients but its combination with azacitidine elicited controversial results.
Francesco D’Alò, Ilaria Zangrilli, Elisa Cupelli, Luana Fianchi, Marianna Criscuolo, Giulia Falconi, Emiliano Fabiani, Livio Pagano, Stefan Hohaus, Valerio De Stefano   +9 more
doaj   +2 more sources

Eltrombopag during induction chemotherapy in older patients with newly diagnosed acute myeloid leukemia is safe and reduces platelet transfusion requirements: The EPAG-2015 French Innovative Leukemia Organization phase 2 randomized trial. [PDF]

Cancer
Abstract Background Elderly patients with acute myeloid leukemia (AML) treated with intensive chemotherapy are at risk of developing thrombopenia, which requires platelet transfusions. It would be interesting to provide them with thrombopoietin receptor agonists such as eltrombopag.
Pigneux A, Dumas PY, Bernard M, Vey N, Bidet A, Mineur A, Schmidt A, Carré M, Ojeda M, Bertoli S, Banos A, Peterlin P, Guièze R, Desbrosses Y, Guepin GR, Simand C, Leguay T, Gyan E, Jourdan E, Vial JP, Marchand T, Hicheri Y, Béné MC, Hamel JF, Récher C.   +24 more
europepmc   +2 more sources

Use of Eltrombopag in Improving Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation

Case Reports in Oncology, 2018
Eltrombopag is a thrombopoietin agonist and has been used in aplastic anemia and post-transplantation thrombocytopenia. The c-MPL receptor is present on hematopoietic stem cells.
Samip Master, Ashish Dwary, Richard Mansour, Glenn M. Mills, Nebu Koshy   +4 more
doaj   +2 more sources

Repurposing FDA-Approved Drugs to Inhibit Fungal PPTases for Broad-Spectrum Synergy. [PDF]

Adv Sci (Weinh)
Fungal secondary metabolites serve as crucial virulence effectors; however, the potential of their biosynthetic pathways as antifungal targets remains inadequately comprehended. Repurposed FDA‐approved drugs inhibit fungal PPTase (essential for secondary metabolism) in vivo.
Song Z, Zhao C, Wang Q, Zhang H, Liu X, Wang L, Bromley M, Yin WB.   +7 more
europepmc   +2 more sources

Reversible Eltrombopag-Associated Bone Marrow Fibrosis With Hematologic Recovery After Drug Withdrawal in <i>ASXL1</i>-Mutated Hypoplastic Myelodysplastic Syndrome: A Case Report. [PDF]

EJHaem
ABSTRACT Hypoplastic myelodysplastic syndrome (MDS) often overlaps clinically with aplastic anemia and frequently involves clonal hematopoiesis. Thrombopoietin receptor agonists (TPO‐RAs), including eltrombopag, are increasingly used to treat cytopenias in hypoplastic marrow failure syndromes; however, their long‐term effects on clonal dynamics and ...
Yoshihara K, Matsuda I, Nannya Y, Samori M, Tomigaki N, Takahashi S, Ohe C, Yoshihara S.   +7 more
europepmc   +2 more sources